Group 1 - Green Leaf Pharmaceutical (02186.HK) announced a share transfer agreement involving Nanjing Green Leaf, a subsidiary, where an investor will transfer 25% of its stake for RMB 1.086 billion to Nanjing Xinshi [1] - Nanjing Xinshi is a limited partnership, with Shandong Green Leaf, a wholly-owned subsidiary, acquiring approximately 33.2% of its partnership interests for RMB 200 million [1] - The remaining interests in Nanjing Xinshi are held by China Cinda (approximately 66.4%) and two general partners, Hangzhou Xinshi and Yantai Hexin, each holding about 0.2% [1] Group 2 - Nanjing Xinshi has the right to request Yantai Green Leaf to repurchase its stake in Nanjing Green Leaf under a share option agreement upon the occurrence of specified events [2] - Yantai Green Leaf has the option to require China Cinda to sell its interests in Nanjing Xinshi, and must also acquire Hangzhou Xinshi's partnership interests if it exercises this option [2] - Following the completion of the share transfer, Nanjing Xinshi will secure bank financing of up to RMB 648 million, with Yantai Green Leaf and Shenzhen Green Leaf providing guarantees for this financing [2]
绿叶制药(02186.HK)：南京信石拟10.86亿元收购南京绿叶25%股权